MX2019001391A - N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. - Google Patents
N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.Info
- Publication number
- MX2019001391A MX2019001391A MX2019001391A MX2019001391A MX2019001391A MX 2019001391 A MX2019001391 A MX 2019001391A MX 2019001391 A MX2019001391 A MX 2019001391A MX 2019001391 A MX2019001391 A MX 2019001391A MX 2019001391 A MX2019001391 A MX 2019001391A
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- fenylsulfonil
- benzamides
- inhibitors
- related compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title 1
- 229940054066 benzamide antipsychotics Drugs 0.000 title 1
- 150000003936 benzamides Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente divulgación proporciona compuestos que tienen la Fórmula I-A: (ver Fórmula) y sus sales y solvatos aceptables desde el punto de vista farmacéutico, en donde A, X1, X2, X3 R1a, R1b, E, y (ver Símbolo) son como se definen en la información de la memoria descriptiva. La presente divulgación también proporciona compuestos de la Fórmula I-A para usar en el tratamiento de una enfermedad, trastorno o afección que responda a la inhibición de la proteína Bcl-2, como el cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371504P | 2016-08-05 | 2016-08-05 | |
| US201762454101P | 2017-02-03 | 2017-02-03 | |
| PCT/US2017/045428 WO2018027097A1 (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019001391A true MX2019001391A (es) | 2019-06-06 |
| MX381588B MX381588B (es) | 2025-03-12 |
Family
ID=59677319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001391A MX381588B (es) | 2016-08-05 | 2017-08-04 | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. |
| MX2020013014A MX2020013014A (es) | 2016-08-05 | 2019-01-31 | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013014A MX2020013014A (es) | 2016-08-05 | 2019-01-31 | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10829488B2 (es) |
| EP (3) | EP3494115B1 (es) |
| JP (2) | JP6651180B2 (es) |
| KR (2) | KR102376764B1 (es) |
| CN (2) | CN110483501B (es) |
| AU (2) | AU2017305508B2 (es) |
| CA (1) | CA3031419C (es) |
| CY (1) | CY1123859T1 (es) |
| DK (1) | DK3494115T3 (es) |
| ES (1) | ES2849959T3 (es) |
| HR (1) | HRP20202073T1 (es) |
| HU (1) | HUE053414T2 (es) |
| IL (2) | IL264059B (es) |
| LT (1) | LT3494115T (es) |
| MX (2) | MX381588B (es) |
| MY (1) | MY199409A (es) |
| PE (1) | PE20190711A1 (es) |
| PH (1) | PH12019500231A1 (es) |
| PT (1) | PT3494115T (es) |
| RS (1) | RS61821B1 (es) |
| RU (2) | RU2722560C1 (es) |
| SA (1) | SA519401020B1 (es) |
| SG (2) | SG11201900135YA (es) |
| SI (1) | SI3494115T1 (es) |
| SM (1) | SMT202100025T1 (es) |
| WO (1) | WO2018027097A1 (es) |
| ZA (2) | ZA201900240B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017156398A1 (en) * | 2016-03-10 | 2017-09-14 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| SG11201900135YA (en) * | 2016-08-05 | 2019-02-27 | Univ Michigan Regents | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| CN116589459B (zh) | 2017-04-18 | 2026-01-30 | 重庆复创医药研究有限公司 | 凋亡诱导剂 |
| KR102738032B1 (ko) | 2018-04-29 | 2024-12-05 | 베이진 엘티디 | Bcl-2 억제제 |
| CA3094449C (en) | 2018-07-31 | 2023-02-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| AU2019315466B2 (en) * | 2018-07-31 | 2022-05-19 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| WO2020024834A1 (en) * | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CN114522167A (zh) | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| AU2019385458A1 (en) * | 2018-11-23 | 2021-01-07 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and use thereof |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| TW202114692A (zh) * | 2019-07-02 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | 一種含有mTOR抑制劑的藥物組合及其應用 |
| AU2020321068A1 (en) * | 2019-07-31 | 2021-03-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| US12516053B2 (en) | 2019-10-28 | 2026-01-06 | Beone Medicines I Gmbh | Bcl-2 inhibitors |
| TWI885019B (zh) | 2019-11-27 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
| EP3914251A4 (en) * | 2019-12-03 | 2022-03-23 | Ascentage Pharma (Suzhou) Co., Ltd. | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS USED AS BCL-2 INHIBITORS |
| CN118542872A (zh) * | 2019-12-04 | 2024-08-27 | 苏州亚盛药业有限公司 | 药物组合及其用途 |
| US20230041515A1 (en) | 2019-12-06 | 2023-02-09 | Loxo Oncology, Inc. | Dosing of a bruton's tyrosine kinase inhibitor |
| WO2021175321A1 (en) * | 2020-03-06 | 2021-09-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystalline forms or amorphous forms of n- (phenyl sulfonyl) benzamide compounds or its salts or solvates |
| US20230128137A1 (en) * | 2020-03-12 | 2023-04-27 | Medshine Discovery Inc. | Benzo five-membered cyclic compound |
| CN116802179A (zh) | 2020-04-15 | 2023-09-22 | 百济神州有限公司 | Bcl-2抑制剂 |
| WO2021227763A1 (en) * | 2020-05-14 | 2021-11-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Hplc analysis method for n- (phenylsulfonyl) benzamide compound |
| CN113880834B (zh) * | 2020-07-01 | 2023-01-20 | 苏州亚盛药业有限公司 | N-(苯基磺酰基)苯甲酰胺类化合物及其中间体的合成方法 |
| CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
| WO2022007940A1 (zh) * | 2020-07-10 | 2022-01-13 | 江苏恒瑞医药股份有限公司 | 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用 |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| JP2023539114A (ja) * | 2020-08-21 | 2023-09-13 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 全身性エリテマトーデスを治療する組成物及び方法 |
| WO2022037683A1 (en) * | 2020-08-21 | 2022-02-24 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| WO2022111558A1 (en) * | 2020-11-25 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Solid dispersion, pharmaceutical preparations, preparation method, and application thereof |
| US20240316069A1 (en) * | 2020-12-28 | 2024-09-26 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods of treating multiple sclerosis |
| JP2024504542A (ja) * | 2021-02-01 | 2024-02-01 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体 |
| US20250319183A1 (en) | 2021-04-07 | 2025-10-16 | David Avigan | Compositions and methods for the treatment of cancer |
| JP2024528174A (ja) | 2021-08-02 | 2024-07-26 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 医薬組合せおよびその使用 |
| EP4442685A4 (en) * | 2021-12-06 | 2025-11-19 | Hangzhou Healzen Therapeutics Co Ltd | BCL-2 PROTEIN ANTI-APOPTOTIC INHIBITOR: PHARMACEUTICAL COMPOSITION AND USES |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
| EP4421075A1 (en) * | 2023-02-27 | 2024-08-28 | KRKA, d.d., Novo mesto | Process for the preparation of venetoclax and intermediates used therein |
| WO2024184233A1 (en) | 2023-03-03 | 2024-09-12 | Ionctura Sa | Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021343A (en) | 1912-01-17 | 1912-03-26 | M A N Mfg Company | Locking-clamp. |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| US7842681B2 (en) | 2006-09-05 | 2010-11-30 | Abbott Laboratories | Treatment of myeoproliferative diseases |
| KR20090087491A (ko) | 2006-12-04 | 2009-08-17 | 아보트 러보러터리즈 | 암 치료요법을 위한 동반 진단 검정 |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| PT2376480T (pt) | 2008-12-05 | 2016-10-26 | Abbvie Inc | Derivados de sulfonamida como agentes indutores de apoptose seletivos de bcl-2 para o tratamento do cancro e de doenças imunes |
| CA2747837A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9045800B2 (en) | 2009-02-11 | 2015-06-02 | Abbvie Inc. | Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers |
| KR101920202B1 (ko) * | 2009-05-26 | 2018-11-21 | 애브비 아일랜드 언리미티드 컴퍼니 | 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| IL225340A (en) | 2010-10-29 | 2017-05-29 | Abbvie Inc | Solid dispersions containing cell mortality |
| SI2643322T1 (en) | 2010-11-23 | 2018-01-31 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| US20120129853A1 (en) | 2010-11-23 | 2012-05-24 | Abbott Laboratories | Methods of treatment using selective bcl-2 inhibitors |
| EP4218572A1 (en) | 2015-12-30 | 2023-08-02 | Dexcom, Inc. | System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile |
| SG11201900135YA (en) * | 2016-08-05 | 2019-02-27 | Univ Michigan Regents | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
-
2017
- 2017-08-04 SG SG11201900135YA patent/SG11201900135YA/en unknown
- 2017-08-04 LT LTEP17754889.8T patent/LT3494115T/lt unknown
- 2017-08-04 US US16/317,056 patent/US10829488B2/en active Active
- 2017-08-04 RU RU2019105721A patent/RU2722560C1/ru active
- 2017-08-04 PT PT177548898T patent/PT3494115T/pt unknown
- 2017-08-04 EP EP17754889.8A patent/EP3494115B1/en active Active
- 2017-08-04 MX MX2019001391A patent/MX381588B/es unknown
- 2017-08-04 HU HUE17754889A patent/HUE053414T2/hu unknown
- 2017-08-04 RS RS20201599A patent/RS61821B1/sr unknown
- 2017-08-04 EP EP19184604.7A patent/EP3569601B1/en active Active
- 2017-08-04 SM SM20210025T patent/SMT202100025T1/it unknown
- 2017-08-04 AU AU2017305508A patent/AU2017305508B2/en active Active
- 2017-08-04 SG SG10201913643YA patent/SG10201913643YA/en unknown
- 2017-08-04 KR KR1020197002744A patent/KR102376764B1/ko active Active
- 2017-08-04 DK DK17754889.8T patent/DK3494115T3/da active
- 2017-08-04 SI SI201730535T patent/SI3494115T1/sl unknown
- 2017-08-04 EP EP22179906.7A patent/EP4129999A1/en active Pending
- 2017-08-04 ES ES17754889T patent/ES2849959T3/es active Active
- 2017-08-04 CN CN201910626474.XA patent/CN110483501B/zh active Active
- 2017-08-04 HR HRP20202073TT patent/HRP20202073T1/hr unknown
- 2017-08-04 MY MYPI2019000239A patent/MY199409A/en unknown
- 2017-08-04 KR KR1020217026744A patent/KR102429704B1/ko active Active
- 2017-08-04 PE PE2019000335A patent/PE20190711A1/es unknown
- 2017-08-04 JP JP2019506191A patent/JP6651180B2/ja active Active
- 2017-08-04 WO PCT/US2017/045428 patent/WO2018027097A1/en not_active Ceased
- 2017-08-04 CN CN201780035965.6A patent/CN109311871B/zh active Active
- 2017-08-04 RU RU2020114660A patent/RU2744358C2/ru active
- 2017-08-04 CA CA3031419A patent/CA3031419C/en active Active
-
2018
- 2018-08-01 US US16/051,816 patent/US10221174B2/en active Active
-
2019
- 2019-01-02 IL IL264059A patent/IL264059B/en active IP Right Grant
- 2019-01-14 ZA ZA2019/00240A patent/ZA201900240B/en unknown
- 2019-01-31 MX MX2020013014A patent/MX2020013014A/es unknown
- 2019-01-31 PH PH12019500231A patent/PH12019500231A1/en unknown
- 2019-02-04 SA SA519401020A patent/SA519401020B1/ar unknown
- 2019-07-23 JP JP2019135624A patent/JP7205903B2/ja active Active
- 2019-12-19 ZA ZA2019/08466A patent/ZA201908466B/en unknown
-
2020
- 2020-09-17 US US17/023,426 patent/US11718613B2/en active Active
-
2021
- 2021-01-15 CY CY20211100032T patent/CY1123859T1/el unknown
- 2021-04-06 IL IL282099A patent/IL282099B/en unknown
- 2021-04-06 AU AU2021202113A patent/AU2021202113B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001391A (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| CL2019000819A1 (es) | Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
| MX2018013433A (es) | Piperidinas como inhibidores de menina. | |
| CL2019001551A1 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| CU24389B1 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| MX2017002670A (es) | Inhibidores de glucosidasa. | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| MX2019001581A (es) | Inhibidores de ssao de aminopirimidina. | |
| MX2017009449A (es) | Inhibidor jak. | |
| CL2018003361A1 (es) | Uso médico de una combinación o composición farmacéutica. | |
| DOP2009000243A (es) | Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer | |
| MX379297B (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| MX2018010191A (es) | Inhibidores de glucosidasa. | |
| CO2019009722A2 (es) | Dendrímeros terapéuticos | |
| MX388515B (es) | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| MX389265B (es) | Aminopirimidinas como inhibidores de alk. | |
| CO2018013020A2 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
| BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
| MX383202B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| MX386798B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| MX2018001576A (es) | Piridinas y su uso en el tratamiento del cancer. |